Edgewise Therapeutics, Inc.

EWTX

US28036F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
19.43 ^USD	+6.29%		+7.88%	+77.61%

Jul. 01	Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Microcap Value Index	CI
Jul. 01	Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000E Value Index	CI

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Small Cap Comp Value Index

July 30, 2024

Latest news about Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Microcap Value Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000E Value Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000E Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Microcap Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 3000 Value Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2500 Value Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 3000E Growth Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 3000 Growth Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2000 Value Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 2000 Growth Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell 2500 Growth Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) added to S&P Pharmaceuticals Select Industry Index	Jun. 23	CI
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating	May. 10	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors	May. 07	CI
Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial	May. 06	MT
Edgewise Therapeutics, Inc Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	May. 06	CI
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	Apr. 23	MT
RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	Apr. 22	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Apr. 16	MT
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	Apr. 15	MT
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	Apr. 15	CI
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	Mar. 28	CI

Chart Edgewise Therapeutics, Inc.

Duration

Period

More charts

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.43 USD

Average target price

32.5 USD

Spread / Average Target

+67.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDGEWISE THERAPEUTICS, INC.	+77.61%	1.81B
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research